Last reviewed · How we verify
Epirubicin, Paclitaxel, Filgrastim
Epirubicin, Paclitaxel, Filgrastim is a Chemotherapy combination (anthracycline + taxane + growth factor) Small molecule drug developed by North Eastern German Society of Gynaecological Oncology. It is currently in Phase 3 development for Breast cancer (likely early-stage or locally advanced, given Phase 3 context and gynaecological oncology focus).
This combination regimen uses an anthracycline chemotherapy agent and a taxane to damage cancer cell DNA and disrupt microtubule formation, supported by a growth factor to maintain bone marrow function.
This combination regimen uses an anthracycline chemotherapy agent and a taxane to damage cancer cell DNA and disrupt microtubule formation, supported by a growth factor to maintain bone marrow function. Used for Breast cancer (likely early-stage or locally advanced, given Phase 3 context and gynaecological oncology focus).
At a glance
| Generic name | Epirubicin, Paclitaxel, Filgrastim |
|---|---|
| Sponsor | North Eastern German Society of Gynaecological Oncology |
| Drug class | Chemotherapy combination (anthracycline + taxane + growth factor) |
| Target | DNA (epirubicin); microtubules (paclitaxel); G-CSF receptor (filgrastim) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin intercalates into DNA and generates reactive oxygen species to kill rapidly dividing cancer cells. Paclitaxel stabilizes microtubules and prevents cell division. Filgrastim (G-CSF) stimulates neutrophil production to mitigate chemotherapy-induced neutropenia. Together, this combination targets breast cancer cells through complementary cytotoxic mechanisms while managing treatment-related myelosuppression.
Approved indications
- Breast cancer (likely early-stage or locally advanced, given Phase 3 context and gynaecological oncology focus)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Cardiotoxicity
- Mucositis
Key clinical trials
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (PHASE3)
- A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (PHASE3)
- Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer (PHASE3)
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I (PHASE4)
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors (PHASE2)
- A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer. (PHASE2)
- Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer (PHASE3)
- Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epirubicin, Paclitaxel, Filgrastim CI brief — competitive landscape report
- Epirubicin, Paclitaxel, Filgrastim updates RSS · CI watch RSS
- North Eastern German Society of Gynaecological Oncology portfolio CI
Frequently asked questions about Epirubicin, Paclitaxel, Filgrastim
What is Epirubicin, Paclitaxel, Filgrastim?
How does Epirubicin, Paclitaxel, Filgrastim work?
What is Epirubicin, Paclitaxel, Filgrastim used for?
Who makes Epirubicin, Paclitaxel, Filgrastim?
What drug class is Epirubicin, Paclitaxel, Filgrastim in?
What development phase is Epirubicin, Paclitaxel, Filgrastim in?
What are the side effects of Epirubicin, Paclitaxel, Filgrastim?
What does Epirubicin, Paclitaxel, Filgrastim target?
Related
- Drug class: All Chemotherapy combination (anthracycline + taxane + growth factor) drugs
- Target: All drugs targeting DNA (epirubicin); microtubules (paclitaxel); G-CSF receptor (filgrastim)
- Manufacturer: North Eastern German Society of Gynaecological Oncology — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (likely early-stage or locally advanced, given Phase 3 context and gynaecological oncology focus)
- Compare: Epirubicin, Paclitaxel, Filgrastim vs similar drugs
- Pricing: Epirubicin, Paclitaxel, Filgrastim cost, discount & access